BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18061933)

  • 1. Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma.
    Lee JA; Kim MS; Kim DH; Lim JS; Yoo JY; Koh JS; Lee SY; Jeon DG; Park KD
    Pediatr Blood Cancer; 2008 Feb; 50(2):195-200. PubMed ID: 18061933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial tumor size predicts histologic response and survival in localized osteosarcoma patients.
    Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
    J Surg Oncol; 2008 Apr; 97(5):456-61. PubMed ID: 18270971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new relative tumor sizing method in epi-metaphyseal osteosarcoma.
    Kim SH; Shin KH; Park EH; Cho YJ; Park BK; Suh JS; Yang WI
    BMC Cancer; 2015 Apr; 15():284. PubMed ID: 25885468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
    Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
    Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
    Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy].
    Rehan N; Bieling P; Winkler P; Helmke K; Maas R; Baldini N; Heise U; Fuchs N; Winkler K
    Klin Padiatr; 1993; 205(4):200-9. PubMed ID: 8377444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor size and prognosis in aggressively treated osteosarcoma.
    Bieling P; Rehan N; Winkler P; Helmke K; Maas R; Fuchs N; Bielack S; Heise U; Jurgens H; Treuner J; Romanowski R; Exner U; Kotz R; Winkler K
    J Clin Oncol; 1996 Mar; 14(3):848-58. PubMed ID: 8622033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
    Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
    Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
    J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy for pediatric osteosarcoma patients.
    Uchida A; Myoui A; Araki N; Yoshikawa H; Shinto Y; Ueda T
    Cancer; 1997 Jan; 79(2):411-5. PubMed ID: 9010116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
    Nataraj V; Batra A; Rastogi S; Khan SA; Sharma MC; Vishnubhatla S; Bakhshi S
    J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.
    Goorin AM; Schwartzentruber DJ; Devidas M; Gebhardt MC; Ayala AG; Harris MB; Helman LJ; Grier HE; Link MP;
    J Clin Oncol; 2003 Apr; 21(8):1574-80. PubMed ID: 12697883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.
    Jeon DG; Song WS; Cho WH; Kong CB; Cho SH
    Clin Orthop Relat Res; 2014 Jun; 472(6):1911-20. PubMed ID: 24574120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.
    Lin F; Wang Q; Yu W; Tang L; Zheng S; Sun Y; Shen Z; Yao Y; Dong Y
    Asia Pac J Clin Oncol; 2011 Sep; 7(3):270-5. PubMed ID: 21884438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response.
    Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jung ST; Jeon DG
    J Orthop Sci; 2009 May; 14(3):292-7. PubMed ID: 19499296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caffeine-potentiated chemotherapy for metastatic osteosarcoma.
    Kimura H; Tsuchiya H; Shirai T; Nishida H; Hayashi K; Takeuchi A; Ohnari I; Tomita K
    J Orthop Sci; 2009 Sep; 14(5):556-65. PubMed ID: 19802667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteosarcoma developed in the period of maximal growth rate have inferior prognosis.
    Lee JA; Kim MS; Kim DH; Lim JS; Park KD; Song WS; Lee SY; Jeon DG
    J Pediatr Hematol Oncol; 2008 Jun; 30(6):419-24. PubMed ID: 18525457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy.
    Hattinger CM; Michelacci F; Sella F; Magagnoli G; Benini S; Gambarotti M; Palmerini E; Picci P; Serra M; Ferrari S
    Histopathology; 2015 Sep; 67(3):338-47. PubMed ID: 25600168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
    Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
    J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.